热门资讯> 正文
Autonomix报告胰腺癌治疗疼痛减轻后股价上涨
2024-09-09 21:21
- Autonomix Medical (NASDAQ:AMIX) stock rose about 5.4% premarket after it announced preliminary results from the first five “lead-in” patients in the ongoing trial evaluating the safety and effectiveness of delivering transvascular energy to mitigate pancreatic cancer pain.
- Responders experienced a pain reduction from a pre-procedure pain score of 8 to a pain score of 1.33 at 4-6 weeks post-procedure.
- 60% of patients responded with a mean 6.67 or 83% reduction of pain on the VAS pain scale at 4-6 weeks post-procedure.
- Reduction of pain score occurred simultaneously as the subject’s underlying disease (pancreatic cancer tumor) continued to grow.
- The company said it is beneficial for patients who are considered end of life, given their advanced stage of disease.
- Source: Press Release
More on Autonomix Medical, Inc.
- IPO Roundup: Pershing Square, Actuate Therapeutics and more
- Autonomix appoints Brad Hauser as CEO
- Historical earnings data for Autonomix Medical, Inc.
- Financial information for Autonomix Medical, Inc.
推荐文章
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
